Immune, inflammatory and cardiovascular consequences of sleep restriction and recovery

Sleep Medicine Reviews

Volumn 16, Issue 2, 2012, Pages 137-149

  Faraut, Brice ^a,b   Boudjeltia, Karim Zouaoui ^a   Vanhamme, Luc ^a   Kerkhofs, Myriam ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cardiovascular risk; Immune cells; Inflammatory marker; Sleep countermeasures; Sleep recovery; Sleep restriction; Stress system

Indexed keywords

C REACTIVE PROTEIN; CATECHOLAMINE; GROWTH HORMONE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MELATONIN; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL POPULATION; CIRCADIAN RHYTHM; CYTOKINE RELEASE; DISEASE COURSE; GENE EXPRESSION; HEALTH HAZARD; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LYMPHOCYTE; MONOCYTE; NATURAL KILLER CELL; NEUROENDOCRINE SYSTEM; NEUTROPHIL COUNT; NIGHT WORK; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; SEX DIFFERENCE; SHEAR STRESS; SHIFT WORKER; SIGNAL TRANSDUCTION; SLEEP DEPRIVATION; SLEEP TIME; SLOW WAVE SLEEP; STRESS; WOMEN'S HEALTH; WORK SCHEDULE;

ADULT; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; IMMUNITY; INFLAMMATION; MALE; NEUROSECRETORY SYSTEMS; SEX FACTORS; SLEEP; SLEEP DEPRIVATION;

EID: 84856799800     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2011.05.001     Document Type: Review

References (123)

1. National Sleep Foundation Sleep in America poll 2009, Available from:. http://www.sleepfoundation.org/sites/default/files/2009%2520Sleep%2520in%2520America%2520SOF%2520EMBARGOED.pdf.
2. Banks S., Dinges D.F. Behavioral and physiological consequences of sleep restriction. JClin Sleep Med 2007, 3:519-528.
3. Meerlo P., Sgoifo A., Suchecki D. Restricted and disrupted sleep: effects on autonomic function, neuroendocrine stress systems and stress responsivity. Sleep Med Rev 2008, 12:197-210.
4. Leproult R., Van Cauter E. Role of sleep and sleep loss in hormonal release and metabolism. Endocr Dev 2010, 17:11-21.
5. Lange T., Dimitrov S., Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci 2010, 1193:48-59.
6. Mullington J.M., Haack M., Toth M., Serrador J.M., Meier-Ewert H.K. Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovasc Dis 2009, 51:294-302.
7. Scheer F.A., Hilton M.F., Mantzoros C.S., Shea S.A. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A 2009, 106:4453-4458.
8. Knutsson A. Health disorders of shift workers. Occup Med (Lond) 2003, 53:103-108.
9. Gangwisch J.E., Heymsfield S.B., Boden-Albala B., Buijs R.M., Kreier F., Pickering T.G., et al. Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep 2007, 30:1667-1673.
10. Cappuccio F.P., D'Elia L., Strazzullo P., Miller M.A. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2010, 33:414-420.
11. Heslop P., Smith G.D., Metcalfe C., Macleod J., Hart C. Sleep duration and mortality: the effect of short or long sleep duration on cardiovascular and all-cause mortality in working men and women. Sleep Med 2002, 3:305-314.
12. Ferrie J.E., Shipley M.J., Cappuccio F.P., Brunner E., Miller M.A., Kumari M., et al. Aprospective study of change in sleep duration: associations with mortality in the Whitehall II cohort. Sleep 2007, 30:1659-1666.
13. Born J., Lange T., Hansen K., Molle M., Fehm H.L. Effects of sleep and circadian rhythm on human circulating immune cells. JImmunol 1997, 158:4454-4464.
14. Zeitzer J.M., Duffy J.F., Lockley S.W., Dijk D.J., Czeisler C.A. Plasma melatonin rhythms in young and older humans during sleep, sleep deprivation, and wake. Sleep 2007, 30:1437-1443.
15. Palmblad J., Cantell K., Strander H., Froberg J., Karlsson C.G., Levi L., et al. Stressor exposure and immunological response in man: interferon-producing capacity and phagocytosis. JPsychosom Res 1976, 20:193-199.
16. Palmblad J., Petrini B., Wasserman J., Akerstedt T. Lymphocyte and granulocyte reactions during sleep deprivation. Psychosom Med 1979, 41:273-278.
17. Dinges D.F., Douglas S.D., Zaugg L., Campbell D.E., McMann J.M., Whitehouse W.G., et al. Leukocytosis and natural killer cell function parallel neurobehavioral fatigue induced by 64hours of sleep deprivation. JClin Invest 1994, 93:1930-1939.
18. Arora V., Dunphy C., Chang V.Y., Ahmad F., Humphrey H.J., Meltzer D. The effects of on-duty napping on intern sleep time and fatigue. Ann Intern Med 2006, 144:792-798.
19. Faraut B., Boudjeltia K.Z., Dyzma M., Rousseau A., David E., Stenuit P., et al. Benefits of napping and an extended duration of recovery sleep on alertness and immune cells after acute sleep restriction. Brain Behav Immun 2011, 25:16-24.
20. Boudjeltia K.Z., Faraut B., Stenuit P., Esposito M.J., Dyzma M., Brohee D., et al. Sleep restriction increases white blood cells, mainly neutrophil count, in young healthy men: a pilot study. Vasc Health Risk Manag 2008, 4:1467-1470.
21. Kerkhofs M., Boudjeltia K.Z., Stenuit P., Brohee D., Cauchie P., Vanhaeverbeek M. Sleep restriction increases blood neutrophils, total cholesterol and low density lipoprotein cholesterol in postmenopausal women: a preliminary study. Maturitas 2007, 56:212-215.
22. Lange T., Perras B., Fehm H.L., Born J. Sleep enhances the human antibody response to hepatitis A vaccination. Psychosom Med 2003, 65:831-835.
23. Spiegel K., Sheridan J.F., Van Cauter E. Effect of sleep deprivation on response to immunization. JAMA 2002, 288:1471-1472.
24. Everson C.A. Sustained sleep deprivation impairs host defense. Am J Physiol 1993, 265:R1148-R1154.
25. Toth L.A., Tolley E.A., Krueger J.M. Sleep as a prognostic indicator during infectious disease in rabbits. Proc Soc Exp Biol Med 1993, 203:179-192.
26. Meier-Ewert H.K., Ridker P.M., Rifai N., Price N., Dinges D.F., Mullington J.M. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001, 47:426-430.
27. Haack M., Reichenberg A., Kraus T., Schuld A., Yirmiya R., Pollmacher T. Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine 2000, 12:694-698.
28. Haack M., Kraus T., Schuld A., Dalal M., Koethe D., Pollmacher T. Diurnal variations of interleukin-6 plasma levels are confounded by blood drawing procedures. Psychoneuroendocrinology 2002, 27:921-931.
29. Vgontzas A.N., Pejovic S., Zoumakis E., Lin H.M., Bixler E.O., Basta M., et al. Daytime napping after a night of sleep loss decreases sleepiness, improves performance, and causes beneficial changes in cortisol and interleukin-6 secretion. Am J Physiol Endocrinol Metab 2007, 292:E253-E261.
30. Frey D.J., Fleshner M., Wright K.P. The effects of 40hours of total sleep deprivation on inflammatory markers in healthy young adults. Brain Behav Immun 2007, 21:1050-1057.
31. Shearer W.T., Reuben J.M., Mullington J.M., Price N.J., Lee B.N., Smith E.O., et al. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. JAllergy Clin Immunol 2001, 107:165-170.
32. Meier-Ewert H.K., Ridker P.M., Rifai N., Regan M.M., Price N.J., Dinges D.F., et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. JAm Coll Cardiol 2004, 43:678-683.
33. Redwine L., Hauger R.L., Gillin J.C., Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. JClin Endocrinol Metab 2000, 85:3597-3603.
34. Irwin M.R., Wang M., Campomayor C.O., Collado-Hidalgo A., Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med 2006, 166:1756-1762.
35. Irwin M.R., Carrillo C., Olmstead R. Sleep loss activates cellular markers of inflammation: sex differences. Brain Behav Immun 2010, 24:54-57.
36. Podrez E.A., Schmitt D., Hoff H.F., Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form invitro. JClin Invest 1999, 103:1547-1560.
37. Zouaoui Boudjeltia K., Moguilevsky N., Legssyer I., Babar S., Guillaume M., Delree P., et al. Oxidation of low density lipoproteins by myeloperoxidase at the surface of endothelial cells: an additional mechanism to subendothelium oxidation. Biochem Biophys Res Commun 2004, 325:434-438.
38. Vgontzas A.N., Zoumakis E., Bixler E.O., Lin H.M., Follett H., Kales A., et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. JClin Endocrinol Metab 2004, 89:2119-2126.
39. Haack M., Sanchez E., Mullington J.M. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep 2007, 30:1145-1152.
40. van Leeuwen W.M., Lehto M., Karisola P., Lindholm H., Luukkonen R., Sallinen M., et al. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS One 2009, 4:e4589.
41. Takahashi Y., Kipnis D.M., Daughaday W.H. Growth hormone secretion during sleep. JClin Invest 1968, 47:2079-2090.
42. Steiger A., Guldner J., Hemmeter U., Rothe B., Wiedemann K., Holsboer F. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology 1992, 56:566-573.
43. Schussler P., Yassouridis A., Uhr M., Kluge M., Weikel J., Holsboer F., et al. Growth hormone-releasing hormone and corticotropin-releasing hormone enhance non-rapid-eye-movement sleep after sleep deprivation. Am J Physiol Endocrinol Metab 2006, 291:E549-E556.
44. Perras B., Marshall L., Kohler G., Born J., Fehm H.L. Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuroendocrinology 1999, 24:743-757.
45. Spath-Schwalbe E., Uthgenannt D., Voget G., Kern W., Born J., Fehm H.L. Corticotropin-releasing hormone-induced adrenocorticotropin and cortisol secretion depends on sleep and wakefulness. JClin Endocrinol Metab 1993, 77:1170-1173.
46. Irwin M., Thompson J., Miller C., Gillin J.C., Ziegler M. Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: clinical implications. JClin Endocrinol Metab 1999, 84:1979-1985.
47. Spiegel K., Leproult R., Colecchia E.F., L'Hermite-Baleriaux M., Nie Z., Copinschi G., et al. Adaptation of the 24-h growth hormone profile to a state of sleep debt. Am J Physiol Regul Integr Comp Physiol 2000, 279:R874-R883.
48. Bjerknes R., Aarskog D. Priming of human polymorphonuclear neutrophilic leukocytes by insulin-like growth factor I: increased phagocytic capacity, complement receptor expression, degranulation, and oxidative burst. JClin Endocrinol Metab 1995, 80:1948-1955.
49. Leproult R., Copinschi G., Buxton O., Van Cauter E. Sleep loss results in an elevation of cortisol levels the next evening. Sleep 1997, 20:865-870.
50. Brohee D., Vanhaeverbeek M., Kennes B., Neve P. Leukocyte and lymphocyte subsets after a short pharmacological stress by intravenous epinephrine and hydrocortisone in healthy humans. Int J Neurosci 1990, 53:53-62.
51. Davis J.M., Albert J.D., Tracy K.J., Calvano S.E., Lowry S.F., Shires G.T., et al. Increased neutrophil mobilization and decreased chemotaxis during cortisol and epinephrine infusions. JTrauma 1991, 31:725-731.
52. Dimitrov S., Lange T., Born J. Selective mobilization of cytotoxic leukocytes by epinephrine. JImmunol 2010, 184:503-511.
53. Rontgen P., Sablotzki A., Simm A., Silber R.E., Czeslick E. Effect of catecholamines on intracellular cytokine synthesis in human monocytes. Eur Cytokine Netw 2004, 15:14-23.
54. van der Poll T., Jansen J., Endert E., Sauerwein H.P., van Deventer S.J. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun 1994, 62:2046-2050.
55. Liao J., Keiser J.A., Scales W.E., Kunkel S.L., Kluger M.J. Role of corticosterone in TNF and IL-6 production in isolated perfused rat liver. Am J Physiol 1995, 268:R699-R706.
56. Liao J., Keiser J.A., Scales W.E., Kunkel S.L., Kluger M.J. Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol 1995, 268:R896-R901.
57. DeRijk R.H., Boelen A., Tilders F.J., Berkenbosch F. Induction of plasma interleukin-6 by circulating adrenaline in the rat. Psychoneuroendocrinology 1994, 19:155-163.
58. Jan B.U., Coyle S.M., Oikawa L.O., Lu S.E., Calvano S.E., Lehrer P.M., et al. Influence of acute epinephrine infusion on endotoxin-induced parameters ofheart rate variability: a randomized controlled trial. Ann Surg 2009, 249:750-756.
59. van der Poll T., Coyle S.M., Barbosa K., Braxton C.C., Lowry S.F. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. JClin Invest 1996, 97:713-719.
60. van der Poll T., Lowry S.F. Lipopolysaccharide-induced interleukin 8 production by human whole blood is enhanced by epinephrine and inhibited by hydrocortisone. Infect Immun 1997, 65:2378-2381.
61. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., Petrov D., et al. Amechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A 2003, 100:1920-1925.
62. Xiao C., Ghosh S. NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv Exp Med Biol 2005, 560:41-45.
63. Irwin M.R., Wang M., Ribeiro D., Cho H.J., Olmstead R., Breen E.C., et al. Sleep loss activates cellular inflammatory signaling. Biol Psychiatry 2008, 64:538-540.
64. Jawien J., Gajda M., Mateuszuk L., Olszanecki R., Jakubowski A., Szlachcic A., et al. Inhibition of nuclear factor-kappaB attenuates artherosclerosis in apoE/LDLR - double knockout mice. JPhysiol Pharmacol 2005, 56:483-489.
65. Muenter N.K., Watenpaugh D.E., Wasmund W.L., Wasmund S.L., Maxwell S.A., Smith M.L. Effect of sleep restriction on orthostatic cardiovascular control in humans. JAppl Physiol 2000, 88:966-972.
66. Sauvet F, Leftheriotis G, Gomez-Merino D, Langrume C, Drogou C, Van Beers P, etal. Effect of acute sleep deprivation on vascular function in healthy subjects. J Appl Physiol; 108: 68-75.
67. Chae C.U., Lee R.T., Rifai N., Ridker P.M. Blood pressure and inflammation in apparently healthy men. Hypertension 2001, 38:399-403.
68. Rogers N.L., Dinges D.F. Interaction of chronic sleep restriction and circadian system in humans. JSleep Res 2008, 17:406-411.
69. Shafer L.L., McNulty J.A., Young M.R. Assessment of melatonin's ability to regulate cytokine production by macrophage and microglia cell types. JNeuroimmunol 2001, 120:84-93.
70. Currier N.L., Sun L.Z., Miller S.C. Exogenous melatonin: quantitative enhancement invivo of cells mediating non-specific immunity. JNeuroimmunol 2000, 104:101-108.
71. Johe P.D., Osterud B. The invivo effect of melatonin on cellular activation processes in human blood during strenuous physical exercise. JPineal Res 2005, 39:324-330.
72. Veneroso C., Tunon M.J., Gonzalez-Gallego J., Collado P.S. Melatonin reduces cardiac inflammatory injury induced by acute exercise. JPineal Res 2009, 47:184-191.
73. Zavodnik I.B., Domanski A.V., Lapshina E.A., Bryszewska M., Reiter R.J. Melatonin directly scavenges free radicals generated in red blood cells and a cell-free system: chemiluminescence measurements and theoretical calculations. Life Sci 2006, 79:391-400.
74. Broncel M., Kozirog-Kolacinska M., Chojnowska-Jezierska J. Melatonin in the treatment of atherosclerosis. Pol Merkur Lekarski 2007, 23:124-127.
75. Rief W, Mills PJ, Ancoli-Israel S, Ziegler MG, Pung MA, Dimsdale JE. Overnight changes of immune parameters and catecholamines are associated with mood and stress. Psychosom Med; 72: 755-762.
76. Kudielka B.M., Kirschbaum C. Sex differences in HPA axis responses to stress: a review. Biol Psychol 2005, 69:113-132.
77. Miller M.A., Kandala N.B., Kivimaki M., Kumari M., Brunner E.J., Lowe G.D., et al. Gender differences in the cross-sectional relationships between sleep duration and markers of inflammation: Whitehall II study. Sleep 2009, 32:857-864.
78. Friedman G.D., Klatsky A.L., Siegelaub A.B. The leukocyte count as a predictor of myocardial infarction. NEngl J Med 1974, 290:1275-1278.
79. Zalokar J.B., Richard J.L., Claude J.R. Leukocyte count, smoking, and myocardial infarction. NEngl J Med 1981, 304:465-468.
80. Vozarova B., Weyer C., Lindsay R.S., Pratley R.E., Bogardus C., Tataranni P.A. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:455-461.
81. Loimaala A., Rontu R., Vuori I., Mercuri M., Lehtimaki T., Nenonen A., et al. Blood leukocyte count is a risk factor for intima-media thickening and subclinical carotid atherosclerosis in middle-aged men. Atherosclerosis 2006, 188:363-369.
82. Brown D.W., Ford E.S., Giles W.H., Croft J.B., Balluz L.S., Mokdad A.H. Associations between white blood cell count and risk for cerebrovascular disease mortality: NHANES II mortality study, 1976-1992. Ann Epidemiol 2004, 14:425-430.
83. Wheeler J.G., Mussolino M.E., Gillum R.F., Danesh J. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J 2004, 25:1287-1292.
84. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998, 279:1477-1482.
85. Ruggiero C., Metter E.J., Cherubini A., Maggio M., Sen R., Najjar S.S., et al. White blood cell count and mortality in the Baltimore longitudinal study of aging. JAm Coll Cardiol 2007, 49:1841-1850.
86. Horne B.D., Anderson J.L., John J.M., Weaver A., Bair T.L., Jensen K.R., et al. Which white blood cell subtypes predict increased cardiovascular risk?. JAm Coll Cardiol 2005, 45:1638-1643.
87. Olivares R., Ducimetiere P., Claude J.R. Monocyte count: a risk factor for coronary heart disease?. Am J Epidemiol 1993, 137:49-53.
88. Klebanoff S.J., Headley C.M. Activation of the human immunodeficiency virus-1 long terminal repeat by respiratory burst oxidants of neutrophils. Blood 1999, 93:350-356.
89. Hochholzer W., Morrow D.A., Giugliano R.P. Novel biomarkers in cardiovascular disease: update. Am Heart J 2010, 160:583-594.
90. Zhang R., Brennan M.L., Fu X., Aviles R.J., Pearce G.L., Penn M.S., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142.
91. Tsimikas S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 2006, 8:55-61.
92. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. NEngl J Med 1997, 336:973-979.
93. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. NEngl J Med 2000, 342:836-843.
94. Patterson CC, Smith AE, Yarnell JW, Rumley A, Ben-Shlomo Y, Lowe GD. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly study. Atherosclerosis; 209: 551-557.
95. Sun J., Sukhova G.K., Wolters P.J., Yang M., Kitamoto S., Libby P., et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007, 13:719-724.
96. Cesari M., Penninx B.W., Newman A.B., Kritchevsky S.B., Nicklas B.J., Sutton-Tyrrell K., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108:2317-2322.
97. Vigushin D.M., Pepys M.B., Hawkins P.N. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. JClin Invest 1993, 91:1351-1357.
98. Chen J., Huang L., Song M., Yu S., Gao P., Jing J. C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells. JCardiovasc Pharmacol 2009, 53:359-367.
99. Zieske A.W., Tracy R.P., McMahan C.A., Herderick E.E., Homma S., Malcom G.T., et al. Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscler Thromb Vasc Biol 2005, 25:1237-1243.
100. Cappuccio F.P., Stranges S., Kandala N.B., Miller M.A., Taggart F.M., Kumari M., et al. Gender-specific associations of short sleep duration with prevalent and incident hypertension: the Whitehall II Study. Hypertension 2007, 50:693-700.
101. Meisinger C., Heier M., Lowel H., Schneider A., Doring A. Sleep duration and sleep complaints and risk of myocardial infarction in middle-aged men and women from the general population: the MONICA/KORA Augsburg cohort study. Sleep 2007, 30:1121-1127.
102. Newman A.B., Spiekerman C.F., Enright P., Lefkowitz D., Manolio T., Reynolds C.F., et al. Daytime sleepiness predicts mortality and cardiovascular disease in older adults. The Cardiovascular Health Study Research Group. JAm Geriatr Soc 2000, 48:115-123.
103. Suarez E.C. Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity. Brain Behav Immun 2008, 22:960-968.
104. King C.R., Knutson K.L., Rathouz P.J., Sidney S., Liu K., Lauderdale D.S. Short sleep duration and incident coronary artery calcification. JAMA 2008, 300:2859-2866.
105. Banks S., Van Dongen H.P., Maislin G., Dinges D.F. Neurobehavioral dynamics following chronic sleep restriction: dose-response effects of one night for recovery. Sleep 2009, 33:1013-1026.
106. Lamond N., Jay S.M., Dorrian J., Ferguson S.A., Jones C., Dawson D. The dynamics of neurobehavioural recovery following sleep loss. JSleep Res 2007, 16:33-41.
107. Belenky G., Wesensten N.J., Thorne D.R., Thomas M.L., Sing H.C., Redmond D.P., et al. Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: a sleep dose-response study. JSleep Res 2003, 12:1-12.
108. Lahl O., Wispel C., Willigens B., Pietrowsky R. An ultra short episode of sleep is sufficient to promote declarative memory performance. JSleep Res 2008, 17:3-10.
109. Takahashi M., Arito H. Maintenance of alertness and performance by a brief nap after lunch under prior sleep deficit. Sleep 2000, 23:813-819.
110. Mednick S., Nakayama K., Stickgold R. Sleep-dependent learning: a nap is as good as a night. Nat Neurosci 2003, 6:697-698.
111. Brooks A., Lack L. Abrief afternoon nap following nocturnal sleep restriction: which nap duration is most recuperative?. Sleep 2006, 29:831-840.
112. Milner C.E., Cote K.A. Benefits of napping in healthy adults: impact of nap length, time of day, age, and experience with napping. JSleep Res 2009, 18:272-281.
113. Leger D., Philip P., Jarriault P., Metlaine A., Choudat D. Effects of a combination of napping and bright light pulses on shift workers' sleepiness at the wheel: a pilot study. JSleep Res 2009, 18:472-479.
114. Naska A., Oikonomou E., Trichopoulou A., Psaltopoulou T., Trichopoulos D. Siesta in healthy adults and coronary mortality in the general population. Arch Intern Med 2007, 167:296-301.
115. Campos H., Siles X. Siesta and the risk of coronary heart disease: results from a population-based, case-control study in Costa Rica. Int J Epidemiol 2000, 29:429-437.
116. Tourlouki E, Polychronopoulos E, Zeimbekis A, Tsakountakis N, Bountziouka V, Lioliou E, etal. The 'secrets' of the long livers in Mediterranean islands: the MEDIS study. Eur J Public Health; 20: 659-664.
117. Tanabe N, Iso H, Seki N, Suzuki H, Yatsuya H, Toyoshima H, etal. Daytime napping and mortality, with a special reference to cardiovascular disease: the JACC study. Int J Epidemiol; 39: 233-243.
118. Rupp T.L., Wesensten N.J., Bliese P.D., Balkin T.J. Banking sleep: realization of benefits during subsequent sleep restriction and recovery. Sleep 2009, 32:311-321.
119. Malmberg B., Kecklund G., Karlson B., Persson R., Flisberg P., Orbaek P. Sleep and recovery in physicians on night call: a longitudinal field study. BMC Health Serv Res 2010, 10:239.
120. Zheng H., Patel M., Hryniewicz K., Katz S.D. Association of extended work shifts, vascular function, and inflammatory markers in internal medicine residents: a randomized crossover trial. JAMA 2006, 296:1049-1050.
121. Akerstedt T., Wright K.P. Sleep loss and fatigue in shift work and shift work disorder. Sleep Med Clin 2009, 4:257-271.
122. Nishitani N., Sakakibara H. Subjective poor sleep and white blood cell count in male Japanese workers. Ind Health 2007, 45:296-300.
123. Sookoian S., Gemma C., Fernandez Gianotti T., Burgueno A., Alvarez A., Gonzalez C.D., et al. Effects of rotating shift work on biomarkers of metabolic syndrome and inflammation. JIntern Med 2007, 261:285-292.